BioNTech and Triastek have entered a research partnership and platform technology licence agreement focusing on the development of 3D-printed oral RNA therapeutics.
The companies will create RNA therapeutics to be delivered orally, using 3D printing technology.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,